Doxycycline hyclate 100 mg oral tablets
Health and Human Services (all) · ASPR/ORM-SNS
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50325F80009 in this department, oldest first.
- Jun 20, 2025 · this noticeAward NoticeCHARTWELL RX LLC · $168.0M
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
This requirement is for the supply of Doxycycline hyclate 100 mg oral tablets.
Who won similar work
5 award notices on SAM.gov in the last 24 months. Matched by: Same office (ASPR/ORM-SNS), same product/service code (PSC) 6505 and NAICS 325412.
Single-winner award sizes (5): middle half $45.5M to $80.5M, median $46.2M; range $16.2M to $397.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| GENENTECH USA, INC | 1 | $397.0M | Jan 31, 2025 |
| Multiple Contract Awards - See Description Atlanta GA USA | 1 | $80.5M | Oct 2, 2026 |
| RAFA LABORATORIES LTD. | 1 | $46.2M | Oct 10, 2025 |
| GLAXOSMITHKLINE LLC | 1 | $45.5M | Oct 10, 2025 |
| HEYLTEX CORPORATION | 1 | $16.2M | Oct 10, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Oct 2, 2026Multiple Contract Awards - See Description Atlanta GA USA$80.5MSNS Pharmaceutical Logistic Replenishment Requirement
- Oct 10, 2025GLAXOSMITHKLINE LLC$45.5MRelenza (Zanamivir) Rotadisk, 5MG
- Oct 10, 2025RAFA LABORATORIES LTD.$46.2MAtropine Auto-Injectors (0.5 mg, 1 mg, and 2 mg)
- Oct 10, 2025HEYLTEX CORPORATION$16.2MPrussian Blue (Radiogardase), Insoluble Cap, 500 mg
- Jan 31, 2025GENENTECH USA, INC$397.0MOseltamivir Phosphate with at Least a 10-year Shelf Life
Competitive landscape
For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 3 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (15 filings)
- 0 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 252 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.